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A NOVEL ROLE OF CITED2 IN CARTILAGE PROTECTION BY SUPPRESSING
ADIPOGENESIS AND PRO-INFLAMMATORY MEDIATORS IN THE INFRAPATELLAR
FAT PAD
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Introduction: Obesity generates a chronic, low-grade inflammation that is suggested
to contribute to cartilage degeneration. The infrapatellar fat pad (IPFP), an adipose
tissue located within the knee joint synovial capsule, may participate in this process.
However, regulatory mechanisms of pro-inflammatory mediator expression in the
IPFPare not fully understood. Cbp/p300-interacting transactivator 2 (CITED2) is ame-
chanically sensitive transcriptional regulator that exerts chondroprotective actions
on cartilage by repressing expression ofmatrixmetalloproteinases (MMPs) in chondro-
cytes. CITED2 deficiency is associated with increased differentiation of aged tendon
stem/progenitor cells into adipocytes. As adipokines andpro-inflammatorymediators
produced in the IPFP exert significant impact on joint inflammation and cartilage
breakdown in osteoarthritis (OA), we tested the hypothesis that CITED2 plays a chon-
droprotective role by, at least in part, suppressing adipogenesis andexpression of adi-
pokines and pro-inflammatory mediators in the IPFP.
Subjects and Methods: Cited2+/- and wild-type (WT) littermates (18 weeks-old,
male, nZ6/group) were subjected to normal (13.5% calories from fat) or high fat
diet (60% calories from fat) and/or subjected to moderate treadmill running
(10m/min) or control (0m/min) for 45 min. Explants of IPFPs from mice subjected
to or not subjected to treadmill running were co-cultured with cartilage from naı¨ve
WT mice. Effects of CITED2 manipulation on adipogenesis was investigated using
murine C3H10T1/2 pluripotent stem cells cultured in adipogenic induction medium.
Results: Cited2 expression decreased following a two week high fat diet in wild-
type mice, which was associated with increased expression of adipokines adipsin
and leptin, adipo-regulatory transcription factor Cebpa, proteolytic enzymes
Mmp13 and Adamts5. Cited2+/- mice on a normal diet mimicked the altered
gene expression changes observed in WT mice on a high fat diet, while Cited2+/-
mice on high fat diet further exaggerated the altered expression of these genes.
Treadmill running led to suppressed expression of adipokines, Cebpa, Pparg,
Mmp13 and Adamts5 in the IPFP in WT mice, but not in Cited2+/- mice. IPFP
from treadmill-run WT mice, co-cultured with naı¨ve WT cartilage, markedly
inhibited the expression of Mmp1, Mmp13, Adamts5, and Il1b in the cartilage.
Such effects were not observed in the cartilage co-cultured with IPFP from
Cited2+/- mice. In vitro, C3H10T1/2 cells transfected with Cited2 wild type
cDNA (WT-Cited2) exhibited significantly reduced adipocyte formation, and
reduced expression of adipocyte marker aP2, adipokines (i.e. adipsin, leptin),
and transcriptional regulators (Cebpa and Pparg), while the cells transfected
with dominant negative Cited2 mutant defective in p300 binding (DN-Cited2)
exhibited no such changes. WT-Cited2, but not DN-Cited2 transfected cells also
reduced Cebpa proteins in a p300 immuno-pull-down complex, while Pparg pro-
teins in the complex were not detected. This data indicates Cited2 represses adi-
pogenic differentiation by, at least partly, competing with Cebpa to bind to the
limited amount of co-factor p300.
Discussion and Conclusion: We identified a novel role of CITED2 in chondroprotec-
tion by suppressing expression of adipokine and pro-inflammatory mediators in the
IPFP. CITED2 plays this role, at least in part, by repressing transactivity of C/ebpa.
Furthermore, we demonstrated that loading-induced CITED2 contributed to the
anti-inflammatory and anti-obesity effects of exercise.
http://dx.doi.org/10.1016/j.jot.2016.06.06261
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Introduction and subjects: The microRNAs (miRNAs) play important roles in many
biological processes such as cell differentiation and apoptosis, so they may be
used in the diagnosis and treatment of many diseases like osteoporosis. Wnt signal-
ling pathways including b-catenin are essential for the skeletal cell proliferation and
bone formation. Low-density lipoprotein receptor-related protein (LRP) 5 and LRP6
are two important co-receptors of the Wnt signaling pathways. However, the exact
roles of these two co-receptors in the skeletal cell proliferation and bone formationare not explicit. This study was designed to evaluate the effects of strontium on the
expression levels of miRNAs and to explore their effects on skeletal cell prolifera-
tion, differentiation, adhesion, and apoptosis. The targets of these miRNAs were
also studied.
Methods: Molecular cloning, cell proliferation assay, cell apoptosis assay, quanti-
tative real-time PCR, luciferase reporter assay, immunofluorescence, western
blot, and other methods were used.
Results: Strontium altered the expression levels of miRNAs in vitro and in vivo.
miR-9-5p, miR-675-5p, and miR-138-5p impaired skeletal cell proliferation and
cell differentiation, and altered cell adhesion. miR-9-5p and miR-675-5p induced
MC3T3-E1 cell apoptosis more specifically than miR-138-5p. In addition, miR-675-
5p induced skeletal cell apoptosis by upregulating Nemo-like kinase (NLK) while
miR-9-5p inhibited ATDC5 cell apoptosis by downregulating NLK. miR-9-5p, miR-
675-5p, and miR-138-5p targeted glycogen synthase kinase 3 b (GSK3b), ATPase
Aminophospholipid Transporter Class I Type 8A Member 2 (ATP8A2), and Eukaryotic
Translation Initiation Factor 4E Binding Protein 1 (EIF4EBP1), respectively. LRP5
promoted skeletal cell proliferation through negatively regulating miR-675-5p
and miR-9-5p. Loss of function of LRP5 resulted in drastic cell apoptosis, increased
negative regulators of osteogenesis, and impaired cell adhesion. Strontium stabi-
lized b-catenin through increasing phosphorylation of LRP6 rather than the levels
of LRP6.
Discussion and conclusion: miR-9-5p, miR-675-5p, and miR-138-5p impaired skel-
etal cell proliferation and differentiation, and altered cell adhesion and apoptosis.
Loss of function of LRP5 resulted in impaired osteogenesis.
Funding/support: This study was supported by NSFC (81371989, 81270967).
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Introduction: Osteoarthritis (OA) is the most common degenerative joint disease.
However, few drugs are available to effectively prevent or treat cartilage degen-
eration. So, as a new agent for chondroprotection, we expect Rebamipide to have
a protective effect on cartilage. Rebamipide is a protective drug used for gastric
mucosal injuries such as gastric ulcer and gastritis and also has protective effects
in a variety of tissue and organ injuries. In this study, we employed in vitro cell
culture using primary cultured chondrocytes from human knee OA and in vivo
mouse models of post-traumatic osteoarthritis to examine the effects of Rebami-
pide on articular cartilage degeneration.
Subjects and Methods: Chondrocytes from patients who underwent total knee
arthroplasty were isolated and plated on 6-well tissue culture plates. Cells were stim-
ulated with recombinant human IL-1b, and then treated with or without Rebamipide
for 24h. The levels of mRNA expression of COL2A, IL-1b, TNF, NF-kB, MMP3, MMP13,
ADAMTS5, TIMP3, bFGF, and TGF were estimated using real-time PCR (between six
to nine samples per gene). The mRNA levels were normalized by GAPDH levels of
each sample. Statistical significance was determined using the Kruskal-Wallis test.
Forty eight-week-old male BALB/c strain mice were used. The anterior cruciate liga-
ment andmedial collateral ligamentwere transected inboth knees (PTOA). The knees
were divided into four groups. The concentrations of Rebamipide were 0 (A), 0.1mg/
kg (B), 1mg/kg (C), and 10mg/kg (D). Mice were injected with Rebamipide into the
knee joint every week. Mice were sacrificed at six weeks after operation. All samples
were underwent haematoxylin and eosin (H-E) staining and safranin-O staining, and
evaluated using the Mankin scoring system and OARSI grading system.
Results: The mRNA expression of COL2A was significantly up-regulated after the
treatment with 500mM and 2500mM of Rebamipide. TIMP3, TGF, bFGFwere also signif-
icantly up-regulated after the treatment with 2500mM of Rebamipide. IL-1b, TNF, NF-
kB, andMMP13were significantly down-regulatedafter the treatmentwith 500mMand
2500mM of Rebamipide. MMP3 and ADAMTS5 were also significantly down-regulated
after the treatment with 2500mM of Rebamipide. Proteoglycan loss and alterations
in surface structurewere observed inA and B, but the articular cartilage hada smooth
surface in C and D. In Mankin scoring system and OARSI grading system, average his-
tological scores were significantly better in C and D than in A.
Discussion and Conclusion: This study demonstrated that Rebamipide up-regulated
the mRNA expression of COL2A and anabolic factors (TIMP3, TGF and bFGF) in
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NF-kB, thus Rebamipide had an anti-inflammatory effect in chondrocytes. Rebami-
pide down-regulated catabolic factors (MMP3, MMP13, and ADAMTS5) in chondro-
cytes. Injection of Rebamipide could prevent articular cartilage degeneration for
six weeks. These findings indicate that intra-articular injection of Rebamipide pre-
vents matrix breakdown and the development of OA. In conclusion, intra-articular
injection of Rebamipide prevented articular cartilage degeneration for six weeks
in murine models of osteoarthritis, Rebamipide down-regulated catabolic factors,
and up-regulated anabolic factors in human chondrocytes. Rebamipide could be
an important candidate for prevention of articular cartilage degeneration.
http://dx.doi.org/10.1016/j.jot.2016.06.06464
STRUCTURAL SIMULATION OF ADENOSINE PHOSPHATE VIA PLUMBAGIN AND
ZOLEDRONIC ACID COMPETITIVELY TARGETS JNK/Erk TO SYNERGISTICALLY
ATTENUATE OSTEOCLASTOGENESIS IN A BREAST CANCER MODEL
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Objective: The treatment of breast cancer and subsequent osteolysis remains a
challenge in clinical settings. The aim of this study was to explore the effect
and mechanism of combined treatment with zoledronic acid (ZA) and plumbagin
(PL), a widely investigated component derived from Plumbago Zeylanica, against
breast cancer and cancer-induced osteoclastogenesis.
Methods: Quantitative synergism was evaluated using Compusyn software with
determined combination index (CI) and drug reduction index (DRI) values. The
attenuated malignancies after dual-drug treatment against breast cancer cells
were evaluated with a CCK-8 assay, flow cytometry, and a transwell assay. The
cancer-associated osteoclast formation in vitro after stimulation of receptor acti-
vator for nuclear factor-kB ligand (RANKL) or conditioned medium from MDA-MB-
231 human breast cancer cells upon murine bone marrow-derived monocytes
(BMMs) and human peripheral blood mononucleated cells (hPBMCs), respectively,
were assessed with tartrate-resistant acid phosphatase (TRAcP) staining. Western
blot, real-time PCR, homogeneous time-resolved fluorescence (HTRF) assay, and
molecular docking were used to unravel the underlying synergistic anti-tumorigen-
esis and anti-osteoclastogenesis mechanisms. Non-invasive imaging system (IVIS),
mCT scanning, and immunohistochemistrical analysis were deployed to investigate
the anti-tumorigenesis and anti-osteoclastogenesis effects in vivo after dual-drug
treatment in an intra-tibiae breast cancer model.
Results: We found that the combination of PL and ZA triggered cytotoxicity
(CIZ0.26), induced apoptosis, and inhibited migration of breast cancer cells syner-
gistically. When the breast cancer cells were transfected with specific siRNA against
Notch-1, the combination of ZA and PL markedly increased the expression of Bcl-2.
Combined treatment also suppressed cell viability of precursor osteoclasts and syn-
ergistically inhibited MDA-MB-231 induced osteoclast formation (CIZ0.28) with the
abrogation of RANKL-induced activation of NF-kB/MAPK pathways. Molecular dock-
ing suggested a putative binding area within JNK/Erk protease active sites through
structural mimicking of adenosine phosphate (ANP) by the spatial combination of
PL with ZA. A HTRF assay further illustrated the direct competitiveness of the
dual drugs against ANP docking to phosphorylated JNK/Erk, contributing to the
inhibited downstream expression of c-Jun/c-Fos/NFATc-1. Then, in vivo testing
demonstrated that the combined administration of PL and ZA attenuated breast
cancer growth in the bone microenvironment. Additionally, these molecules pre-
vented the destruction of the proximal tibia, with significant reduction of TRAcP
positive osteoclast cells and potentiation of apoptotic cancer cells, to a greater
extent when combined than when the drugs were applied independently.
Conclusion: The combination treatment with PL and ZA could significantly and
synergistically inhibit tumorigenesis and suppress osteoclastogenesis both in vitro
and in vivo by modulating Notch-1-Bcl-2 signalling and simulating the spatial struc-
ture of adenosine phosphate to competitively inhibit phosphorylation of JNK/Erk.
http://dx.doi.org/10.1016/j.jot.2016.06.06567
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Introduction: Tenascin-C (TNC) is an extracellular matrix glycoprotein. While the
expression is repressed in normal adult tissues, it reappears under pathological
conditions such as wound healing, regeneration, and tumorigenesis. In articular
cartilage, TNC expression is associated with development and is almost absent inadult cartilage. In diseased joints, including those with osteoarthritis (OA), TNC
was highly recurring in cartilage. Our previous studies have demonstrated that
full-length TNC promoted chondrocyte proliferation and increased proteoglycan
content in vitro, and promoted the repair of full-thickness osteochondral defects
in rabbits. In this study, we examined the effects of full-length TNC on joint carti-
lage repair and on synovial inflammation in full-thickness osteochondral defects
model mice. In addition, we performed an in vitro study to reveal the mechanism
of repairing cartilage using full-length TNC.
Methods: Full-length TNC was purified from culture supernatant of human glioma
cells U-251 MG. Male 8-week-old BALB/c strain mice were used. In vivo study: Full-
thickness osteochondral defects were created in the centre of the femoral
trochlea with a hand micro-drill equipped with a 0.3-mm diameter drill-bit. The
defect was filled with TNC (group A: 100mg/ml, group B: 10mg/ml, group C: empty)
by direct administration. Mice were sacrificed at 1, 2, 3, and 6 weeks postopera-
tively (nZ10 knees in each groups at every time point), and whole knee joints
were removed by dissection. Histological examinations were made using haema-
toxylin & eosin (H-E) and Safranin-O (Saf-O) staining. Cartilage repair was evalu-
ated using the modified WAKITANI score. Synovitis was evaluated using synovitis
score according to Krenn. In vitro study: Human cartilage specimens were obtained
from patients who underwent total knee arthroplasty for the treatment of OA.
Chondrocytes were isolated and cultured and they were treated with 0mg/ml,
1mg/ml, or 10mg/ml of TNC. We compared the expression of numerous kinds of
mRNA for every dose by real-time PCR. We evaluated the expression of TNC, in-
flammatory cytokines [TNF-a, IL-1b], anabolic factors [TGFb, TIMP3, bFGF], and
catabolic factors [ADAMTS4, 5, and MMP3, 13].
Results: In vivo study: In Saf-O-staining, the defects in Group A were covered with
hyaline-like cartilage at 3 and 6 weeks. Average modified WAKITANI scores were
significantly better in group A than group B and C at 3 and 6 weeks [3weeks: group
A: 6.2, group B: 7.8, group C: 9.8 (p<0.05); 6weeks: group A: 6.4, group B: 7.6,
group C: 8.6 (p<0.05)]. At 1 and 2 weeks, there was no significant difference in
the average scores in all groups. Low-grade synovitis occurred in both groups at
each week. There were no significant differences in average synovitis scores be-
tween the two groups at each day. In vitro study: Both 1mg/ml and 10mg/ml of
TNC up-regulated the expression of TNFa and IL-1b. 10mg/ml TNC up-regulated
the expression of endogenous TNC, TGFb, TIMP3 and ADAMTS4, MMP3, MMP13,
but 10mg/ml of TNC down-regulated the expression of ADAMTS5.
Conclusion: This study demonstrated that full-thickness osteochondral defects in
mice with 100mg/ml of TNC were successfully repaired with hyaline-like cartilage
without exacerbating synovitis. The in vitro study demonstrated that TNC up-reg-
ulates itself and anabolic factors. TNC up-regulated the expression of ADAMTS4,
but down-regulated the expression of ADAMTS5, which contributed to cartilage
degradation. We consider that TNC could repair the cartilage using these
mechanisms.
http://dx.doi.org/10.1016/j.jot.2016.06.06675
ADVANCED MUSCULOSKELETAL IMAGING SYSTEMS ADOPTED FOR STUDYING A
NOVEL BONE-TARGETING DELIVERY SYSTEM CARRYING OSTEOPROMOTIVE
PHYTOMOLECULE(S) DEVELOPED FOR THE PREVENTION OF OESTROGEN
DEPLETION-INDUCED OSTEOPOROSIS
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Introduction: Epimedium is a usual herb used in herbal Fufang (formula) in TCM to
strengthen bone and Icaritin is the most potential metabolite of Epimedium. This
study was designed to develop an Icaritin-containing bone targeting delivery sys-
tem for evaluation of its prevention effects on estrogen-depletion induced osteo-
porosis in experimental model.
Subjects and Methods: To evaluate the efficacy of Icaritin with targeting liposome
delivery system on prevention of osteoporosis in vivo by analyzing the bone quality
and microarchitecture by micro-computed tomography (micro-CT) and the organ
distribution of the delivery system by using Xenogen IVIS spectrum system. (DSS6)-
liposome-Icaritin was firstly synthesized by thin film evaporation method with
extruding through polycarbonate filter membranes to obtain unilamellar vesicles.
Then the bone targeting molecules DSS6 were attached to the surface of the
vesicles. Eighty 4-month-old C57/BL6 female mice were divided into 9 groups
(nZ10), including Baseline (BL), Sham surgery (SH), Ovariectomized only (OVX),
Estradiol for oral administration (O-E2), Icaritin for oral administration (O-ICT),
low dose (8 mg/kg, 1/week) targeting liposome delivery system with Icaritin
injected via caudal vein (IV-LIP+ICT+DSS6-L), high dose (8 mg/kg, 2/week) targeting
liposome delivery systemwith Icaritin injected via caudal vein (IV-LIP+ICT+DSS6-H),
liposome delivery systemwith Icaritin injected via caudal vein (IV-LIP+ICT, 8 mg/kg,
2/week). Except in the BL and SH groups, ovariectomy surgery (OVX) was performed
on other mice. Administration of gavage and IV injection were applied respectively
from the day right after the surgery and lasted for 6weeks. All micewere sacrificed 6
weeks after surgery. Lumbar spine and the lower limbswere harvest for bone quality
analysis. Proximal tibia was scanned by micro-CT (Scanco micro-CT 40). Trabecular
bone was identified and the parameters including bone mineral density (BMD),
